Welcome to our dedicated page for Cardiol Therapeu news (Ticker: CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeu stock.
News about Cardiol Therapeutics Inc. (CRDL) centers on its progress as a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Headlines frequently highlight updates from the company’s key clinical programs, including the MAVERIC Program in recurrent pericarditis and the ARCHER trial in acute myocarditis, both of which evaluate its lead small-molecule drug candidate, CardiolRx™.
Investors following CRDL news can expect detailed coverage of clinical milestones such as database lock, topline results, and comprehensive data presentations from randomized, double-blind, placebo-controlled trials. Recent releases describe notable improvements in cardiac magnetic resonance imaging measures in acute myocarditis and progress in the pivotal Phase III MAVERIC trial, which focuses on preventing recurrent pericarditis episodes and reducing symptoms like chest pain and inflammation.
Company news also reports on regulatory and strategic developments, including Orphan Drug Designation for CardiolRx™ in pericarditis, Investigational New Drug authorizations, and intellectual property advances. For example, Cardiol has announced a U.S. patent allowance for cannabidiol compositions for treating heart conditions, expected to protect the use of CardiolRx™ and CRD-38 across a range of cardiac disorders into late 2040.
Additional news items cover financings that support the company’s clinical programs and extend its operating runway, as well as participation in scientific and investor conferences where management discusses trial data and development plans. This news page aggregates these updates so readers can monitor Cardiol Therapeutics’ ongoing clinical results, regulatory milestones, financing activities, and pipeline progress in inflammatory heart disease.
Cardiol Therapeutics (NASDAQ: CRDL) announced expansion of its pivotal Phase III MAVERIC trial in the U.S., planning up to seven additional clinical centers to reach an anticipated total of 25 sites.
Patient enrollment has reached 75%, with target recruitment expected by end of Q2 2026 but potentially extending into Q3 2026. MAVERIC is a randomized, placebo-controlled trial of CardiolRx™ designed with FDA alignment and intended to support a future NDA.
Cardiol Therapeutics (NASDAQ: CRDL) announced a live interview with Barchart on X today, April 14, 2026, at 12:00 PM EDT featuring CEO David Elsley. Topics include the pivotal Phase III MAVERIC trial for recurrent pericarditis, published Phase II ARCHER myocarditis results, and next-gen drug CRD-38.
Investors can join live at x.com/Barchart; a full recording will be posted on Cardiol's X channel (@CardiolRx) and Barchart's channel after the event.
Cardiol Therapeutics (NASDAQ: CRDL) reported year-end 2025 operational progress: initiated pivotal Phase III MAVERIC in recurrent pericarditis (>50% enrolled; full enrollment expected Q2 2026), reported positive Phase II ARCHER results (LV mass reduction of -9.2g, p=0.0117), advanced CRD-38 toward IND/Phase I, received a U.S. patent allowance through Oct 2040, strengthened its board, and raised $31M in financings, funding operations into Q4 2027.
Key priorities include completing MAVERIC enrollment, initiating CRD-38 clinical work, and pursuing strategic partnerships.
Cardiol Therapeutics (NASDAQ: CRDL) will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026 at 10:30 a.m. EST.
A live webcast and a replay will be available under Events & Presentations in the Investors section of the company website.
Cardiol Therapeutics (NASDAQ: CRDL) announced publication of its Phase II ARCHER study in ESC Heart Failure on February 10, 2026. The randomized, double‑blind, placebo‑controlled trial in 109 patients reported a significant reduction in left ventricular mass versus placebo (-9.2 g; p=0.0117), decreased left atrial remodelling, favorable trends in myocardial inflammation markers, and a safety/tolerability profile. The authors and company highlight relevance of these biological signals to Cardiol's ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis, citing myocarditis–pericarditis overlap and potential implications for inflammation‑driven structural heart damage.
Cardiol Therapeutics (NASDAQ: CRDL) closed a private placement on January 23, 2026, raising $14.85 million through the issuance of 11,423,078 Units at $1.30 per Unit, including full exercise of the over‑allotment option. Each Unit comprises one common share and one‑half of a warrant; each whole warrant is exercisable at $1.75 for 24 months. Canaccord Genuity acted as sole underwriter and the company paid a 6% cash commission. Net proceeds are intended for research and clinical development, general and administrative expenses, working capital, and other expenses. The offering was completed as a private placement under Canadian prospectus exemptions and the securities are not registered in the United States.
Cardiol Therapeutics (NASDAQ: CRDL) entered a bought deal private placement to issue 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million, with an underwriter option to sell up to an additional 1,038,462 units to raise up to $1.35 million. Each unit includes one common share and one-half warrant; each full warrant exercisable at $1.75 for 24 months.
The offering is expected to close on or about January 23, 2026, is subject to TSX approvals and customary conditions, and the company intends to use net proceeds to advance research and clinical development and for general corporate purposes.
Cardiol Therapeutics (NASDAQ: CRDL) announced it has surpassed 50% patient enrollment in MAVERIC, its pivotal Phase III randomized, double-blind, placebo-controlled trial of CardiolRx for recurrent pericarditis. More than 15 U.S. cardiovascular centers are actively enrolling, with additional sites in Europe and Canada being activated. MAVERIC plans ~110 patients across ~25 centers, a primary endpoint of freedom from new recurrent pericarditis at 6 months, and secondary endpoints including pericarditis pain days, pain score changes, and CRP. Full enrollment is expected in Q2 2026.
Cardiol Therapeutics (NASDAQ: CRDL) reported Phase II ARCHER results showing CardiolRx™ produced structural heart improvements in acute myocarditis after 12 weeks.
Key measured effects included a -9.2 g reduction in left ventricular (LV) mass versus placebo (p=0.0117) and a -8.1 mL reduction in left atrial end systolic volume (p=0.0376). Other CMR endpoints changed numerically but did not reach conventional statistical significance. Safety was reported as balanced between groups.
Cardiol Therapeutics (NASDAQ: CRDL) received a U.S. Notice of Allowance for a patent titled "Cannabidiol Compositions for Use in Treating Heart Conditions", which upon issuance will protect use of CardiolRx and CRD-38 for a broad range of cardiac disorders through October 2040.
The allowance expands the company's global IP portfolio alongside granted and pending patents in Europe, Japan, Canada, Australia, and China, and complements its U.S. Orphan Drug Designation for pericarditis. Management said the allowance supports late-stage programs in recurrent pericarditis and acute myocarditis and upcoming first-in-human evaluation of CRD-38. The company plans to present ARCHER topline data on November 29, 2025, and will update on Phase III MAVERIC enrollment progress.